Text Size

Screening for Urinary Incontinence by Primary Care Providers

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Gunhilde Buchsbaum, University of Rochester
ClinicalTrials.gov Identifier:
NCT00178334
First received: September 12, 2005
Last updated: January 28, 2013
Last verified: January 2013
History of Changes
  Purpose

The purpose of this study is to:

  • Assess the rate of screening for urinary incontinence (UI) in women by their primary care providers
  • Identify the type of screening used by primary care providers
  • Identify barriers to screening for UI
  • Identify differences in screening rates between specialties
  • Assess whether primary care providers view UI as a serious medical problem
  • Assess the comfort level of primary care providers in the diagnosis and treatment of UI
  • Identify primary care providers' preferred mode of learning more about UI

Condition
Urinary Incontinence

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Screening for Urinary Incontinence by Primary Care Providers

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Rochester:

Primary Outcome Measures:
  • Questionnaire [ Time Frame: Response to mailing ] [ Designated as safety issue: No ]

Enrollment: 554
Study Start Date: March 2006
Study Completion Date: July 2006
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)
Detailed Description:

UI is a very common condition whose prevalence can be expected to increase dramatically in the coming decades. Treatment options are available to improve women's health and quality of life. However, inadequate communication between physicians and patients leads to decreased diagnosis and treatment. Past studies evaluating the use of screening by primary care providers, who act as gatekeepers in our healthcare system, clearly demonstrate that improvements must be made in the screening system. We propose a survey of local primary care providers to quantify screening rates for UI and identify barriers to successful screening. The information collected in this survey will allow us to identify methods such as targeted education opportunities and patient literature or questionnaires that will assist providers and their patients in initiating discussion and evaluation of UI.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Primary care providers

Criteria

Inclusion Criteria:

  • All primary care providers in the Greater Rochester metropolitan area, including: Primary care Medical Doctors (MD), Doctors of Osteopathy (DO), Primary care Nurse Practitioners (NP), and Physician Assistants (PA)

Exclusion Criteria:

  • Physicians in the Greater Rochester metropolitan area who are not primary care providers
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00178334

Sponsors and Collaborators
University of Rochester
Pfizer
Investigators
Principal Investigator: Gunhilde Buchsbaum, MD University of Rochester
  More Information

No publications provided

Responsible Party: Gunhilde Buchsbaum, Associate Professor, University of Rochester
ClinicalTrials.gov Identifier: NCT00178334     History of Changes
Other Study ID Numbers: 11355
Study First Received: September 12, 2005
Last Updated: January 28, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Urinary Incontinence
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on May 19, 2013